/INSM
INSM Stock - Insmed Incorporated
Healthcare|Medical - PharmaceuticalsNASDAQ
$163.72-2.38%
$4.00 (-2.38%) • Jan 13
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+31.2%upside
Target: $214.80
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INSM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$162.08 – $165.36
TARGET (TP)$214.88
STOP LOSS$150.62
RISK/REWARD1:3.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.09
52W High$212.75
52W Low$60.40
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $363.71M | $305.21M | $245.36M | $188.46M | $164.41M |
| Gross Profit | $277.96M | $239.63M | $190.23M | $144.31M | $124.54M |
| Gross Margin | 76.4% | 78.5% | 77.5% | 76.6% | 75.7% |
| Operating Income | $-878,252,000 | $-709,626,000 | $-457,321,000 | $-375,094,000 | $-265,232,000 |
| Net Income | $-913,772,000 | $-749,567,000 | $-481,534,000 | $-434,654,000 | $-294,090,000 |
| Net Margin | -251.2% | -245.6% | -196.3% | -230.6% | -178.9% |
| EPS | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 |
Company Overview
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
92%
Hold / Neutral
1
8%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish1 Neutral/Bearish
Price Targets
$97
Average Target
↓ 40.8% Downside
Now
$28
Low
$97
Average
$263
High
Based on 16 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2025 | Truist | Resumed | Buy | $202 |
| December 4th 2025 | Rothschild & Co Redburn | Initiation | Buy | $263 |
| October 28th 2025 | Cantor Fitzgerald | Resumed | Overweight | $192 |
| October 20th 2025 | Wells Fargo | Initiation | Overweight | $171 |
| August 20th 2025 | William Blair | Initiation | Outperform | - |
| August 13th 2025 | Morgan Stanley | Downgrade | Equal Weight | $126 |
| May 13th 2025 | Jefferies | Initiation | Buy | $105 |
| February 25th 2025 | RBC Capital Mkts | Initiation | Outperform | $100 |
| April 23rd 2024 | Truist | Initiation | Buy | $48 |
| February 15th 2024 | Wolfe Research | Initiation | Outperform | $42 |
| December 8th 2023 | Wells Fargo | Initiation | Overweight | $55 |
| November 20th 2023 | JP Morgan | Resumed | Overweight | $36 |
| July 26th 2023 | Guggenheim | Initiation | Buy | $50 |
| December 9th 2022 | Mizuho | Initiation | Buy | $28 |
| December 7th 2022 | Barclays | Initiation | Overweight | $37 |
Earnings History & Surprises
INSMBeat Rate
17%
Last 18 quarters
Avg Surprise
-15.0%
EPS vs Estimate
Beats / Misses
3/15
Last 12 quarters
Latest EPS
$-1.75
Q4 2025
EPS Surprise History
Q1 24
-13.3%
$-1.28vs$-1.13
Q2 24
+14.5%
$-1.06vs$-1.24
Q3 24
-56.5%
$-1.94vs$-1.24
Q4 24
-5.8%
$-1.27vs$-1.20
Q1 25
-12.8%
$-1.32vs$-1.17
Q2 25
-6.0%
$-1.42vs$-1.34
Q3 25
-30.8%
$-1.70vs$-1.30
Q4 25
-31.6%
$-1.75vs$-1.33
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-1.33 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-1.33 | $-1.75 | -31.6% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.30 | $-1.70 | -30.8% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-1.34 | $-1.42 | -6.0% | ✗ MISS |
Q1 2025 | Feb 20, 2025 | $-1.17 | $-1.32 | -12.8% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $-1.20 | $-1.27 | -5.8% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-1.24 | $-1.94 | -56.5% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-1.24 | $-1.06 | +14.5% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-1.13 | $-1.28 | -13.3% | ✗ MISS |
Q4 2023 | Oct 26, 2023 | $-1.06 | $-1.10 | -3.8% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-1.10 | $-1.78 | -61.8% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-1.08 | $-1.17 | -8.3% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-1.00 | $-1.20 | -20.0% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $-0.89 | $-1.09 | -22.5% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.89 | $-0.80 | +10.1% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.91 | $-0.80 | +12.1% | ✓ BEAT |
Q1 2022 | Feb 17, 2022 | $-0.89 | $-0.95 | -6.7% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $-0.83 | $-0.96 | -15.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.85 | $-0.94 | -10.6% | ✗ MISS |
Latest News
Insmed shares are trading higher after the company reported FY25 sales results.
📈 PositiveBenzinga•Jan 9, 2026, 01:53 PM
Insmed Reports $606M in 2025 Revenue as Sales Jump 67% YoY
📈 PositiveBenzinga•Jan 9, 2026, 12:10 PM
UBS Maintains Buy on Insmed, Lowers Price Target to $215
➖ NeutralBenzinga•Jan 6, 2026, 05:59 PM•Also:
TD Cowen Maintains Buy on Insmed, Lowers Price Target to $241
📈 PositiveBenzinga•Dec 18, 2025, 05:48 PM
Goldman Sachs Maintains Buy on Insmed, Lowers Price Target to $225
➖ NeutralBenzinga•Dec 18, 2025, 05:31 PM
HC Wainwright & Co. Maintains Buy on Insmed, Lowers Price Target to $230
📈 PositiveBenzinga•Dec 18, 2025, 04:52 PM
Insmed shares are trading lower after the company announced the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms.
📉 NegativeBenzinga•Dec 18, 2025, 01:55 PM
Guggenheim Maintains Buy on Insmed, Lowers Price Target to $221
➖ NeutralBenzinga•Dec 18, 2025, 01:39 PM
RBC Capital Maintains Outperform on Insmed, Lowers Price Target to $195
📈 PositiveBenzinga•Dec 18, 2025, 01:36 PM
Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 17, 2025, 09:25 PM
Insmed Halts Brensocatib CRSsNP Program After Phase 2b Misses Both Primary And Secondary Endpoints; Acquires Phase 2 Ready Monoclonal Antibody For Potential Respiratory And Immunological & Inflammatory Indications
📉 NegativeBenzinga•Dec 17, 2025, 09:02 PM
Trading Halt: Halted at 4:00:11 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 17, 2025, 09:00 PM
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $234
📈 PositiveBenzinga•Dec 16, 2025, 03:04 PM
Cantor Fitzgerald Maintains Overweight on Insmed, Raises Price Target to $230
📈 PositiveBenzinga•Dec 16, 2025, 01:43 PM
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $258
📈 PositiveBenzinga•Dec 15, 2025, 05:49 PM
Reported Friday, Nasdaq-100 Index Reconstituted As Alnylam, Ferrovial, Insmed, Monolithic Power, Seagate And Western Digital Join, While Biogen, CDW, GlobalFoundries, Lululemon, ON Semiconductor And Trade Desk Exit
➖ NeutralBenzinga•Dec 15, 2025, 08:10 AM•Also: , ,
TD Cowen Maintains Buy on Insmed, Raises Price Target to $269
📈 PositiveBenzinga•Dec 11, 2025, 04:48 PM
Mizuho Maintains Outperform on Insmed, Raises Price Target to $256
📈 PositiveBenzinga•Dec 1, 2025, 01:53 PM
TD Cowen Maintains Buy on Insmed, Raises Price Target to $231
📈 PositiveBenzinga•Nov 20, 2025, 03:48 PM
Insmed Wins EU Approval For BRINSUPRI, The First Treatment For Non-Cystic Fibrosis Bronchiectasis In Patients 12 Years Of Age And Older With Two Or More Exacerbations In The Prior 12 Months
📈 PositiveBenzinga•Nov 18, 2025, 04:03 PM
Frequently Asked Questions about INSM
What is INSM's current stock price?
Insmed Incorporated (INSM) is currently trading at $163.72 per share. The stock has moved -2.38% today.
What is the analyst price target for INSM?
The average analyst price target for INSM is $214.88, based on 1 analyst.
What sector is Insmed Incorporated in?
Insmed Incorporated operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the NASDAQ exchange.
What is INSM's market cap?
Insmed Incorporated has a market capitalization of $34.92 billion, making it a large-cap company.
Does INSM pay dividends?
No, Insmed Incorporated does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorA
Agilent Technologies, Inc.
$146.32
Mkt Cap: $41.5B
ALC
Alcon Inc.
$78.99
Mkt Cap: $39.1B
CAH
Cardinal Health, Inc.
$208.26
Mkt Cap: $49.5B
GEHC
GE HealthCare Technologies Inc.
$84.77
Mkt Cap: $38.7B
HLN
Haleon plc
$9.82
Mkt Cap: $44.5B
HUM
Humana Inc.
$273.96
Mkt Cap: $33.0B
IQV
IQVIA Holdings Inc.
$241.57
Mkt Cap: $41.1B
ONC
BeOne Medicines Ltd.
$351.06
Mkt Cap: $37.5B
RMD
ResMed Inc.
$254.67
Mkt Cap: $37.3B
TAK
Takeda Pharmaceutical Company Limited
$16.01
Mkt Cap: $50.5B
Explore stocks similar to INSM for comparison